13 patients with colorectal cancer participated in the drug trial. All of them had a rare genetic mutation of the tumor — a deficiency of corrective repair. This means that cells are worse at correcting errors in DNA, which, in turn, increases the risk of developing cancer.
8 out of 13 patients also had Lynch syndrome, a hereditary disease that leads to DCR.
Scientists have found that drugs like dostarlimap (Jemperli) are effective against cancers that have arisen as a result of such diseases.
Clinical studies have shown that therapy with this drug gives unprecedented results. The effectiveness turned out to be 100%, and this despite the fact that the patients were not subjected to either radio or chemotherapy, as well as any surgical operations.
Scientists warn that the results are still far from final. However, preliminary data suggest that the drug may be a breakthrough in the treatment of colorectal cancer.